- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06932263
Doseområde Funnstudie For å vurdere effektivitet og sikkerhet for Tozorakimab hos voksne med ukontrollert astma på mellomstore til høy dose inhalerte kortikosteroider (Umbriel)
En fase IIB, multisenter, dobbeltblind, placebokontrollert doseområde Funnstudie for å vurdere effekt og sikkerhet for Tozorakimab hos voksne deltakere med ukontrollert astma på middels til høy dose inhalerte kortikosteroider
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studiesteder
-
-
-
CABA, Argentina, C1425BEN
- Rekruttering
- Research Site
-
Ciudad de Buenos Aires, Argentina, 1128
- Tilbaketrukket
- Research Site
-
Ciudad de Buenos Aires, Argentina, 1425
- Rekruttering
- Research Site
-
La Plata, Argentina, B1900
- Rekruttering
- Research Site
-
Mendoza, Argentina, 5500
- Rekruttering
- Research Site
-
Rosario, Argentina, 2000
- Rekruttering
- Research Site
-
San Miguel de Tucumán, Argentina, 4000
- Rekruttering
- Research Site
-
-
-
-
-
Caxias do Sul, Brasil, 95070-560
- Tilbaketrukket
- Research Site
-
Criciúma, Brasil, 88811-000
- Rekruttering
- Research Site
-
Porto Alegre, Brasil, 91350-200
- Rekruttering
- Research Site
-
Porto Alegre, Brasil, 90610-001
- Rekruttering
- Research Site
-
Salvador, Brasil, 40050 410
- Tilbaketrukket
- Research Site
-
Santo André, Brasil, 09080-110
- Tilbaketrukket
- Research Site
-
Sorocaba, Brasil, 18040-425
- Rekruttering
- Research Site
-
São José do Rio Preto, Brasil, 15090-000
- Rekruttering
- Research Site
-
São Paulo, Brasil, 05403-000
- Rekruttering
- Research Site
-
São Paulo, Brasil, 04014-002
- Rekruttering
- Research Site
-
-
-
-
-
Curicó, Chile, 3341643
- Aktiv, ikke rekrutterende
- Research Site
-
Quillota, Chile, 2260000
- Aktiv, ikke rekrutterende
- Research Site
-
Santiago, Chile, 7500657
- Aktiv, ikke rekrutterende
- Research Site
-
Santiago, Chile, 7501126
- Aktiv, ikke rekrutterende
- Research Site
-
Santiago, Chile, 7750495
- Aktiv, ikke rekrutterende
- Research Site
-
Temuco, Chile, 4810345
- Aktiv, ikke rekrutterende
- Research Site
-
Viña del Mar, Chile, 2540488
- Aktiv, ikke rekrutterende
- Research Site
-
-
-
-
-
Iloilo City, Filippinene, 5000
- Rekruttering
- Research Site
-
Las Piñas, Filippinene, 1742
- Tilbaketrukket
- Research Site
-
Lipa, Filippinene, 4217
- Rekruttering
- Research Site
-
Manadaluyong City, Filippinene, 1552
- Rekruttering
- Research Site
-
Quezon City, Filippinene, 1100
- Rekruttering
- Research Site
-
Roxas City, Filippinene, 5800
- Tilbaketrukket
- Research Site
-
-
-
-
California
-
Bakersfield, California, Forente stater, 93301
- Rekruttering
- Research Site
-
Huntington Beach, California, Forente stater, 92647
- Tilbaketrukket
- Research Site
-
La Mesa, California, Forente stater, 91942
- Avsluttet
- Research Site
-
Loma Linda, California, Forente stater, 92354
- Tilbaketrukket
- Research Site
-
Long Beach, California, Forente stater, 90815
- Rekruttering
- Research Site
-
Newport Beach, California, Forente stater, 92663
- Rekruttering
- Research Site
-
San Jose, California, Forente stater, 95117
- Rekruttering
- Research Site
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19805
- Avsluttet
- Research Site
-
-
Florida
-
Cutler Bay, Florida, Forente stater, 33189
- Suspendert
- Research Site
-
Hialeah, Florida, Forente stater, 33015
- Suspendert
- Research Site
-
Leesburg, Florida, Forente stater, 34748
- Tilbaketrukket
- Research Site
-
Miami, Florida, Forente stater, 33175
- Suspendert
- Research Site
-
Miami, Florida, Forente stater, 33155
- Suspendert
- Research Site
-
Miami Lakes, Florida, Forente stater, 33016
- Suspendert
- Research Site
-
Orlando, Florida, Forente stater, 32819
- Suspendert
- Research Site
-
Palmetto Bay, Florida, Forente stater, 33157
- Suspendert
- Research Site
-
Tampa, Florida, Forente stater, 33607
- Suspendert
- Research Site
-
Winter Park, Florida, Forente stater, 32789
- Suspendert
- Research Site
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Tilbaketrukket
- Research Site
-
-
Indiana
-
Noblesville, Indiana, Forente stater, 46060
- Rekruttering
- Research Site
-
-
Iowa
-
West Des Moines, Iowa, Forente stater, 50266
- Avsluttet
- Research Site
-
-
Kansas
-
Hutchinson, Kansas, Forente stater, 67502
- Rekruttering
- Research Site
-
Kansas City, Kansas, Forente stater, 66160
- Tilbaketrukket
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40218
- Rekruttering
- Research Site
-
-
Maryland
-
White Marsh, Maryland, Forente stater, 21162
- Tilbaketrukket
- Research Site
-
-
Massachusetts
-
Worcester, Massachusetts, Forente stater, 01605
- Rekruttering
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, Forente stater, 48336
- Rekruttering
- Research Site
-
Warren, Michigan, Forente stater, 48088
- Tilbaketrukket
- Research Site
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63141
- Tilbaketrukket
- Research Site
-
-
Nebraska
-
Bellevue, Nebraska, Forente stater, 68123
- Tilbaketrukket
- Research Site
-
Grand Island, Nebraska, Forente stater, 68803
- Rekruttering
- Research Site
-
Omaha, Nebraska, Forente stater, 68134
- Rekruttering
- Research Site
-
-
New Jersey
-
Millville, New Jersey, Forente stater, 08332
- Har ikke rekruttert ennå
- Research Site
-
Mullica Hill, New Jersey, Forente stater, 08062
- Rekruttering
- Research Site
-
Toms River, New Jersey, Forente stater, 08755
- Rekruttering
- Research Site
-
-
New York
-
Horseheads, New York, Forente stater, 14845
- Rekruttering
- Research Site
-
Maspeth, New York, Forente stater, 11378
- Rekruttering
- Research Site
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28803
- Tilbaketrukket
- Research Site
-
Huntersville, North Carolina, Forente stater, 28078
- Tilbaketrukket
- Research Site
-
Kings Mountain, North Carolina, Forente stater, 28086
- Rekruttering
- Research Site
-
Pinehurst, North Carolina, Forente stater, 28374
- Tilbaketrukket
- Research Site
-
-
Ohio
-
Toledo, Ohio, Forente stater, 43617
- Rekruttering
- Research Site
-
-
Oklahoma
-
Edmond, Oklahoma, Forente stater, 73034
- Tilbaketrukket
- Research Site
-
-
Oregon
-
Grants Pass, Oregon, Forente stater, 97527
- Tilbaketrukket
- Research Site
-
Medford, Oregon, Forente stater, 97504
- Rekruttering
- Research Site
-
Portland, Oregon, Forente stater, 97202
- Rekruttering
- Research Site
-
-
Pennsylvania
-
DuBois, Pennsylvania, Forente stater, 15801
- Avsluttet
- Research Site
-
Philadelphia, Pennsylvania, Forente stater, 19140
- Rekruttering
- Research Site
-
Smithfield, Pennsylvania, Forente stater, 15478
- Rekruttering
- Research Site
-
-
South Carolina
-
Rock Hill, South Carolina, Forente stater, 29732
- Rekruttering
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37919
- Avsluttet
- Research Site
-
-
Texas
-
Austin, Texas, Forente stater, 78759
- Rekruttering
- Research Site
-
Boerne, Texas, Forente stater, 78006
- Rekruttering
- Research Site
-
Dallas, Texas, Forente stater, 75254
- Rekruttering
- Research Site
-
El Paso, Texas, Forente stater, 79912
- Rekruttering
- Research Site
-
Forney, Texas, Forente stater, 75126
- Avsluttet
- Research Site
-
Greenville, Texas, Forente stater, 75401
- Rekruttering
- Research Site
-
Kingwood, Texas, Forente stater, 77339
- Rekruttering
- Research Site
-
McKinney, Texas, Forente stater, 75069
- Tilbaketrukket
- Research Site
-
Sugar Land, Texas, Forente stater, 77478
- Rekruttering
- Research Site
-
Victoria, Texas, Forente stater, 77901
- Rekruttering
- Research Site
-
-
Utah
-
Roy, Utah, Forente stater, 84067
- Avsluttet
- Research Site
-
-
Washington
-
Bellingham, Washington, Forente stater, 98225
- Avsluttet
- Research Site
-
-
West Virginia
-
Kingwood, West Virginia, Forente stater, 26537
- Rekruttering
- Research Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53228
- Rekruttering
- Research Site
-
-
-
-
-
Brest, Frankrike, 29200
- Rekruttering
- Research Site
-
Créteil, Frankrike, 94010
- Rekruttering
- Research Site
-
Lyon, Frankrike, 69317
- Rekruttering
- Research Site
-
Marseille, Frankrike, 13015
- Rekruttering
- Research Site
-
Pessac, Frankrike, 33604
- Rekruttering
- Research Site
-
Strasbourg, Frankrike, 67091
- Rekruttering
- Research Site
-
Suresnes, Frankrike, 92150
- Rekruttering
- Research Site
-
-
-
-
-
Athens, Hellas, 11521
- Aktiv, ikke rekrutterende
- Research Site
-
Athens, Hellas, 17562
- Aktiv, ikke rekrutterende
- Research Site
-
Ioannina, Hellas, 45500
- Tilbaketrukket
- Research Site
-
Pátrai, Hellas, 26504
- Aktiv, ikke rekrutterende
- Research Site
-
Thessaloniki, Hellas, 57010
- Aktiv, ikke rekrutterende
- Research Site
-
Thessaloniki, Hellas, 57001
- Suspendert
- Research Site
-
-
-
-
-
Belagavi, India, 590010
- Rekruttering
- Research Site
-
Coimbatore, India, 641028
- Rekruttering
- Research Site
-
Dehradun, India, 248001
- Rekruttering
- Research Site
-
Delhi, India, 110029
- Rekruttering
- Research Site
-
Faridabad, India, 121012
- Tilbaketrukket
- Research Site
-
Gūrgaon, India, 122001
- Tilbaketrukket
- Research Site
-
Kochi, India, 682027
- Avsluttet
- Research Site
-
Lucknow, India, 226003
- Suspendert
- Research Site
-
New Delhi, India, 110005
- Rekruttering
- Research Site
-
Vadodara, India, 391760
- Rekruttering
- Research Site
-
-
-
-
-
Haifa, Israel, 3109601
- Rekruttering
- Research Site
-
Jerusalem, Israel, 91120
- Rekruttering
- Research Site
-
Kfar Saba, Israel, 44281
- Rekruttering
- Research Site
-
Ramat Gan, Israel, 52621
- Rekruttering
- Research Site
-
Rehovot, Israel, 76100
- Rekruttering
- Research Site
-
-
-
-
-
Catania, Italia, 95123
- Rekruttering
- Research Site
-
Foggia, Italia, 71100
- Rekruttering
- Research Site
-
Genoa, Italia, 16132
- Rekruttering
- Research Site
-
Roma, Italia, 00168
- Rekruttering
- Research Site
-
-
-
-
-
Fukuoka, Japan, 811-1394
- Rekruttering
- Research Site
-
Ginowan-shi, Japan, 901-2214
- Rekruttering
- Research Site
-
Hiroshima, Japan, 730-0013
- Rekruttering
- Research Site
-
Ishinomaki, Japan, 986-8522
- Rekruttering
- Research Site
-
Kawaguchi-shi, Japan, 332-8558
- Rekruttering
- Research Site
-
Kiyose-shi, Japan, 204-8585
- Rekruttering
- Research Site
-
Kobe, Japan, 650-0017
- Rekruttering
- Research Site
-
Meguro-ku, Japan, 152-8902
- Rekruttering
- Research Site
-
Miura, Japan, 238-0111
- Rekruttering
- Research Site
-
Neyagawa, Japan, 572-8551
- Rekruttering
- Research Site
-
Sapporo, Japan, 064-0804
- Rekruttering
- Research Site
-
Sapporo, Japan, 060-0033
- Rekruttering
- Research Site
-
Takamatsu, Japan, 761-8073
- Rekruttering
- Research Site
-
Ube, Japan, 755-8505
- Rekruttering
- Research Site
-
Yokohama, Japan, 232-0066
- Rekruttering
- Research Site
-
Yokohama, Japan, 245-8575
- Rekruttering
- Research Site
-
Yokohama, Japan, 232-0024
- Rekruttering
- Research Site
-
-
-
-
-
Baotou, Kina, 014010
- Rekruttering
- Research Site
-
Changchun, Kina, 130021
- Rekruttering
- Research Site
-
Chengdu, Kina, 610000
- Rekruttering
- Research Site
-
Chongqing, Kina, 400010
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510163
- Rekruttering
- Research Site
-
Haikou, Kina, 570311
- Rekruttering
- Research Site
-
Hefei, Kina, 230061
- Rekruttering
- Research Site
-
Hohhot, Kina, 10050
- Rekruttering
- Research Site
-
Huizhou, Kina, 516001
- Rekruttering
- Research Site
-
Qingdao, Kina, 266011
- Rekruttering
- Research Site
-
Shanghai, Kina, 200025
- Rekruttering
- Research Site
-
Shanghai, Kina, 200065
- Rekruttering
- Research Site
-
Shanghai, Kina, 201114
- Rekruttering
- Research Site
-
Shenzhen, Kina, 518020
- Rekruttering
- Research Site
-
Wenzhou, Kina, 325027
- Rekruttering
- Research Site
-
Xuzhou, Kina, 221000
- Rekruttering
- Research Site
-
-
-
-
-
Lima, Peru, 15046
- Aktiv, ikke rekrutterende
- Research Site
-
Lima, Peru, LIMA 21
- Tilbaketrukket
- Research Site
-
Lima, Peru, 15088
- Aktiv, ikke rekrutterende
- Research Site
-
Lima, Peru, LIMA 33
- Tilbaketrukket
- Research Site
-
Lima, Peru, 15082
- Aktiv, ikke rekrutterende
- Research Site
-
Lima, Peru, LIMA 1
- Aktiv, ikke rekrutterende
- Research Site
-
-
-
-
-
Barcelona, Spania, 08003
- Rekruttering
- Research Site
-
Barcelona, Spania, 8025
- Rekruttering
- Research Site
-
Madrid, Spania, 28041
- Rekruttering
- Research Site
-
Málaga, Spania, 29010
- Rekruttering
- Research Site
-
Mérida, Spania, 06800
- Tilbaketrukket
- Research Site
-
Patraix, Spania, 46017
- Rekruttering
- Research Site
-
Santander, Spania, 39008
- Rekruttering
- Research Site
-
-
-
-
-
Cheongju-si, Sør -Korea, 28644
- Aktiv, ikke rekrutterende
- Research Site
-
Daegu, Sør -Korea, 42415
- Aktiv, ikke rekrutterende
- Research Site
-
Seoul, Sør -Korea, 03080
- Rekruttering
- Research Site
-
Seoul, Sør -Korea, 03722
- Aktiv, ikke rekrutterende
- Research Site
-
Seoul, Sør -Korea, 08308
- Aktiv, ikke rekrutterende
- Research Site
-
Seoul, Sør -Korea, 05505
- Aktiv, ikke rekrutterende
- Research Site
-
Seoul, Sør -Korea, 03312
- Aktiv, ikke rekrutterende
- Research Site
-
Seoul, Sør -Korea, 06591
- Fullført
- Research Site
-
-
-
-
-
Bellville, Sør-Afrika, 7530
- Rekruttering
- Research Site
-
Benoni, Sør-Afrika, 1501
- Rekruttering
- Research Site
-
Brackenfell, Sør-Afrika, 7560
- Rekruttering
- Research Site
-
Cape Town, Sør-Afrika, 7700
- Rekruttering
- Research Site
-
Durban, Sør-Afrika, 4093
- Rekruttering
- Research Site
-
Somerset West, Sør-Afrika, 7130
- Rekruttering
- Research Site
-
eMkhomazi, Sør-Afrika, 4170
- Rekruttering
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Rekruttering
- Research Site
-
New Taipei City, Taiwan, 231
- Tilbaketrukket
- Research Site
-
Taichung, Taiwan, 40705
- Rekruttering
- Research Site
-
Taichung, Taiwan, 433004
- Rekruttering
- Research Site
-
Taipei, Taiwan, 10002
- Rekruttering
- Research Site
-
Taipei, Taiwan, 11220
- Rekruttering
- Research Site
-
Taipei, Taiwan, 110
- Rekruttering
- Research Site
-
Taipei, Taiwan, 11696
- Rekruttering
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10700
- Rekruttering
- Research Site
-
Chanthaburi, Thailand, 22000
- Rekruttering
- Research Site
-
Chiang Rai, Thailand, 57000
- Rekruttering
- Research Site
-
Chon Buri, Thailand, 20000
- Rekruttering
- Research Site
-
Khon Kaen, Thailand, 40002
- Rekruttering
- Research Site
-
Nakhon Sri Thammarat, Thailand, 80000
- Rekruttering
- Research Site
-
-
-
-
-
Adana, Tyrkia (Türkiye), 01330
- Rekruttering
- Research Site
-
Ankara, Tyrkia (Türkiye), 06280
- Rekruttering
- Research Site
-
Bursa, Tyrkia (Türkiye), 16059
- Rekruttering
- Research Site
-
Gaziantep, Tyrkia (Türkiye), 27470
- Rekruttering
- Research Site
-
Istanbul, Tyrkia (Türkiye), 34890
- Rekruttering
- Research Site
-
Kayseri, Tyrkia (Türkiye), 38039
- Rekruttering
- Research Site
-
Mersin, Tyrkia (Türkiye), 33079
- Rekruttering
- Research Site
-
-
-
-
-
Balassagyarmat, Ungarn, 2660
- Aktiv, ikke rekrutterende
- Research Site
-
Budapest, Ungarn, 1121
- Tilbaketrukket
- Research Site
-
Budapest, Ungarn, 1036
- Tilbaketrukket
- Research Site
-
Debrecen, Ungarn, 4032
- Aktiv, ikke rekrutterende
- Research Site
-
Gödöllő, Ungarn, 2100
- Aktiv, ikke rekrutterende
- Research Site
-
Pécs, Ungarn, 7635
- Aktiv, ikke rekrutterende
- Research Site
-
Törökbálint, Ungarn, 2045
- Aktiv, ikke rekrutterende
- Research Site
-
-
-
-
-
Da Nang, Vietnam, 550000
- Rekruttering
- Research Site
-
Haiphong, Vietnam, 180000
- Rekruttering
- Research Site
-
Hanoi, Vietnam, 100000
- Rekruttering
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Rekruttering
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Tilbaketrukket
- Research Site
-
Ho Chi Minh City, Vietnam, 10000
- Rekruttering
- Research Site
-
Huế, Vietnam, 530000
- Rekruttering
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Provision of signed and dated written informed consent prior to any study-specific procedures.
-
Adults aged 18-75, inclusive when signing the informed consent.
-
Documented physician-diagnosis of asthma for at least 12 months.
-
Treated with medium or high dose ICS in combination with LABA.
-
Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 .
-
Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal.
-
Documented exacerbation history in the last 12 months and biomarker requirements of:
- ≥ 2 severe exacerbations OR
- 1 severe exacerbation and:
(i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb
-
Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary.
-
Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
- Completed treatment for respiratory infection with antibiotics in the 4 weeks prior to Visit 1.
- Clinically significant pulmonary disease other than asthma .
- Current smokers, former smokers with >10 pack-years history.
- Clinically significant aortic stenosis or pulmonary arterial hypertension.
- Active tuberculosis, hepatitis, HIV, or current diagnosis of cancer or immune complex disease.
- Unstable cardiovascular disorders.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Tozorakimab Dose 1
Dosing subcutaneously tozorakimab Dose 1 |
The drug will be administered subcutaneously. |
|
Eksperimentell: Tozorakimab Dose 2
Dosing subcutaneously tozorakimab Dose 2 and placebo |
The drug will be administered subcutaneously. |
|
Placebo komparator: Placebo
Dosing subcutaneously with equivalent volume to tozorakimab |
Placebo will be administered subcutaneously. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Annualised rate of severe asthma exacerbations
Tidsramme: Over 26 to 52 weeks
|
The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and ≥ 1 severe exacerbation within 12 months prior to screening. |
Over 26 to 52 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Annualised rate of severe asthma exacerbations
Tidsramme: Over 26 to 52 weeks
|
The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and baseline eosinophils < 300 cells/µL and history of ≥2 severe exacerbations within 12 months prior to screening. |
Over 26 to 52 weeks
|
|
Time to first severe asthma exacerbation
Tidsramme: Over 26 to 52 weeks
|
To evaluate the effect of two dose levels of tozorakimab compared to placebo on time to first severe asthma exacerbations. |
Over 26 to 52 weeks
|
|
Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1)
Tidsramme: Over weeks 20 to 26
|
Difference in mean change from baseline between tozorakimab and placebo. |
Over weeks 20 to 26
|
|
Change from baseline in post-bronchodilator FEV1
Tidsramme: At week 26
|
Difference in mean change from baseline between tozorakimab and placebo. |
At week 26
|
|
Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6)
Tidsramme: At week 26
|
Difference in mean change from baseline between tozorakimab and placebo. The ACQ-6 has 6 questions (regarding asthma symptoms and rescue bronchodilator use). Answering the questions results in a score out of 6. A Score of 0 indicates complete control and 6 reflects severely uncontrolled disease. |
At week 26
|
|
Change from baseline in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ12+)
Tidsramme: At week 26
|
Difference in mean change from baseline between tozorakimab and placebo. The AQLQ12+ includes 32 questions grouped into four domains: symptoms; activity limitations; emotional function; and, environmental stimuli. Each question is scored on a seven-point Likert scale, which ranges from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean of all questions, and the four domain scores are the means of the scores for the questions in the respective domains. |
At week 26
|
|
Trough serum concentrations of tozorakimab
Tidsramme: Over 52 weeks
|
Pharmacokinetics: concentrations of tozorakimab in trough serum. |
Over 52 weeks
|
|
Anti-drug antibody incidence
Tidsramme: Over 52 weeks
|
Immunogenicity: Number of Participants With Positive Antibodies to tozorakimab |
Over 52 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- D9181C00002
- 2024-519116-14-00 (Registeridentifikator: CTIS)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tilgangskriterier for IPD-deling
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .